Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akero Therapeutics ( (AKRO) ) has issued an update.
On September 23, 2025, Akero Therapeutics completed a voluntary prepayment of $37.6 million, settling all obligations under a loan agreement with Hercules Capital. This action fully discharged the company’s debts, potentially strengthening its financial position and operational flexibility.
The most recent analyst rating on (AKRO) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Akero Therapeutics stock, see the AKRO Stock Forecast page.
Spark’s Take on AKRO Stock
According to Spark, TipRanks’ AI Analyst, AKRO is a Neutral.
Akero’s stock score reflects strong technical momentum and positive corporate developments, which are key drivers. However, financial challenges with no current revenue and operational losses weigh down the overall score. The promising clinical trial results provide a potential catalyst for future growth.
To see Spark’s full report on AKRO stock, click here.
More about Akero Therapeutics
Akero Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for serious metabolic diseases.
Average Trading Volume: 1,057,772
Technical Sentiment Signal: Buy
Current Market Cap: $3.82B
For a thorough assessment of AKRO stock, go to TipRanks’ Stock Analysis page.